Hims & Hers Health reported Q2 results on August 10 and the reaction was swift and negative — the stock fell 3.4% the next day and is now down 5.1% on the week to $30.51, extending a month-long slide of more than 11%.
The positioning story is genuinely complex here. Short interest is running at 27.8% of free float — roughly 61 million shares — a level that has been broadly stable over the past six weeks, oscillating between 58 million and 64 million shares without a decisive directional move. The real shift this week is in the lending market: availability has loosened dramatically, climbing to 53.6% from around 32% a week ago. That means the borrow pool has expanded relative to shares already lent, making it considerably easier for new shorts to establish positions if they choose to. Cost to borrow, at just 0.71%, is close to its lowest level in six weeks and well below the 1.2% reading from early July — a further signal that no squeeze pressure exists. The one data point adding tension to an otherwise settled short market is options: the put/call ratio jumped to 0.66 on Tuesday, almost 2.7 standard deviations above its 20-day average of 0.58. That's the sharpest defensive lean in the options market in months, suggesting that at least one cohort of investors moved quickly to buy downside protection after the earnings release.
The Street's reaction to the print tells a split story. Most analysts lifted price targets — Morgan Stanley raised to $28 from $21, TD Cowen moved to $30 from $25, B of A Securities to $32 from $30, and Needham to $42 from $35 — yet every one of those firms kept ratings at Hold, Equal-Weight, or Neutral. The sole exception was Citigroup, which actually trimmed its target to $33 from $35 while staying Neutral. The mean price target now sits at $31.15, barely above the current price of $30.51. That narrow gap between where the stock trades and where analysts think it's worth is itself a signal: the Street sees little room for error. The bull case centres on the Novo partnership and a potential path to $1 billion in revenue through branded GLP-1 distribution. The bear case points to compounding pharmacy regulation risk, margin pressure from the shift toward branded drugs, and a lowered FY26 outlook. The ORTEX short score of 70.6 ranks in the 6th percentile of the universe — meaning 94% of stocks carry a less bearish short-side signal — though that score has been essentially flat for the past two weeks, suggesting no fresh escalation in short-side conviction post-earnings.
One ownership detail worth noting: BlackRock added over 2.3 million shares in July to reach 12.4% of shares outstanding, making it the largest institutional holder by a wide margin. Founder and CEO Andrew Dudum holds 7.8% personally. On the other side, insider selling has been consistent — the CFO sold roughly 32,000 shares across three transactions between June and July at prices ranging from $32 to $36, all above current levels. Renaissance Technologies trimmed its position by 2.7 million shares as of March. The net insider picture over 90 days is technically positive at roughly 490,000 shares net, but the awards component inflates that figure — the cash transactions run the other way.
With the next earnings event not scheduled until November 2, the immediate catalyst calendar is quiet. The tension to watch is whether the loosening in the borrow market invites fresh short supply at these price levels, or whether the expanded availability reflects covering rather than new positioning — the direction of short interest over the next two weeks will be the clearest read on which way that resolves.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
